Precipio (PRPO) Stock Price, News & Analysis

Company Overview

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.

Key Stats

• Today's Range: $5.56 to $6.09
• 50-Day Range: $5.56 to $10.14
• 52-Week Range: $4.31 to $10.74
• Volume: 2,653 shs
• Average Volume: 7,886 shs
• Market Capitalization: $8.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Precipio Stock Analysis - MarketRank™

Precipio scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Precipio.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Precipio is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Precipio is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Precipio has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.00% of the float of Precipio has been sold short.

Short Interest Ratio / Days to Cover

Precipio has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Precipio has recently increased by 19.63%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Precipio does not currently pay a dividend.

Dividend Growth

Precipio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.00% of the float of Precipio has been sold short.

Short Interest Ratio / Days to Cover

Precipio has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Precipio has recently increased by 19.63%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.9 / 5
• News Sentiment: -0.38

News Sentiment

Precipio has a news sentiment score of -0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Precipio this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Precipio insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.30% of the stock of Precipio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 10.45% of the stock of Precipio is held by institutions.

PRPO Stock Analysis - Frequently Asked Questions

How have PRPO shares performed this year?

Precipio's stock was trading at $5.54 at the beginning of the year. Since then, PRPO stock has increased by 0.4% and is now trading at $5.56.
View the best growth stocks for 2025 here.

How were Precipio's earnings last quarter?

Precipio, Inc. (NASDAQ:PRPO) posted its earnings results on Thursday, March, 27th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.74 by $0.97. The biotechnology company earned $5.45 million during the quarter, compared to analysts' expectations of $8.01 million. Precipio had a negative net margin of 17.23% and a negative trailing twelve-month return on equity of 34.01%.

When did Precipio's stock split?

Shares of Precipio reverse split on Friday, September 22nd 2023. The 1-20 reverse split was announced on Friday, September 22nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Precipio?

Shares of PRPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Precipio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Precipio investors own include NVIDIA (NVDA), Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD) and General Electric (GE).

Company Calendar

• Last Earnings: 3/27/2025
• Today: 4/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:PRPO
• CIK: 1043961
• Web: www.precipiodx.com
• Phone: (203) 787-7888
• Fax: 402-452-5401
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,850,000.00
• Net Margins: -17.23%
• Pretax Margin: -17.23%
• Return on Equity: -34.01%
• Return on Assets: -25.27%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 0.73
• Quick Ratio: 0.60

Sales & Book Value

• Annual Sales: $17.41 million
• Price / Sales: 0.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.16 per share
• Price / Book: 0.57

Miscellaneous

• Outstanding Shares: 1,482,000
• Free Float: 1,285,000
• Market Cap: $8.63 million
• Optionable: No Data
• Beta: 1.37